Pipeline

In-house drug development

Compound/Candidate	Radionuclide	Type	Indication	Discovery	Pre-clinical	Regulatory	First-In-Human	Phase 1
18F-DualFAPi DualFAPi-7 Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	18F	β+ (PET)	FAP Expressing Tumors
Radionuclide: 18F Type: β+ (PET) Indication: FAP Expressing Tumors Phase: pre-clinical Candidate: TetraKit Description: Target: Fibroblast Activation Protein (FAP) Partner/co-funding: Co-funded by the European Union under the IHI project.
123I-DualFAPi DualFAPi-5 Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	123I	γ (SPECT)	FAP Expressing Tumors
Radionuclide: 123I Type: γ (SPECT) Indication: FAP Expressing Tumors Phase: discovery Candidate: TetraKit Description: Target: Fibroblast Activation Protein (FAP) Partner/co-funding: Co-funded by the European Union under the EIC Accelerator project
131I-DualFAPi DualFAPi-5 Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	131I	β⁻ (therapy)	FAP Expressing Tumors
Radionuclide: 131I Type: β⁻ (therapy) Indication: FAP Expressing Tumors Phase: pre-clinical Candidate: TetraKit Description: Target: Fibroblast Activation Protein (FAP) Partner/co-funding: Co-funded by the European Union under the EIC Accelerator project
211At-DualFAPi DualFAPi-5 Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	211At	α (therapy)	FAP Expressing Tumors
Radionuclide: 211At Type: α (therapy) Indication: FAP Expressing Tumors Phase: discovery Candidate: TetraKit Description: Target: Fibroblast Activation Protein (FAP) Partner/co-funding: Co-funded by the European Union under the IHI project.
18F-FlutraProst PSMA-TBD Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	18F	β+ (PET)	Prostate cancer
Radionuclide: 18F Type: β+ (PET) Indication: Prostate cancer Phase: first-in-human Candidate: TetraKit Description: Target: PSMA Partner/co-funding: Co-funded by Eurostars
18F-FlutraTate OCT-TBD Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	18F	β+ (PET)	NETs
Radionuclide: 18F Type: β+ (PET) Indication: NETs Phase: pre-clinical Candidate: TetraKit Description: Target: SSTR/ Octreotate Partner/co-funding: Co-funded by the European Union under the IHI project.
211At-AstraTate OCT-TBD Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	211At	α (therapy)	NETs
Radionuclide: 211At Type: α (therapy) Indication: NETs Phase: discovery Candidate: TetraKit Description: Target: SSTR/Octreotate Partner/co-funding: Co-funded by Innovation Fund Denmark

Platform Partnerships

Compound/Candidate	Radionuclide	Type	Indication	Discovery	Pre-clinical	Regulatory	First-In-Human	Phase 1
18F-FlutraHexin TVX-01 Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	18F	β+ (PET)	Pancreatic cancer
Radionuclide: 18F Type: β+ (PET) Indication: Pancreatic cancer Phase: pre-clinical Candidate: TetraKit Description: Target: αvβ6 integrin Partner/co-funding: TRIMT
3BP (211At) 3BP-TBD Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	211At	α (therapy)	Undisclosed
Radionuclide: 211At Type: α (therapy) Indication: Undisclosed Phase: discovery Candidate: TetraKit Description: Target: Undisclosed Partner/co-funding: 3B Pharmaceuticals
AmbiTag for Pretargeting AmbiTag Phase: Discovery Pre-clinical Regulatory First-In-Human Phase 1	131I/211At	β⁻ / α (therapy)	Epithelial-derived cancers
Radionuclide: 131I/211At Type: β⁻ / α (therapy) Indication: Epithelial-derived cancers Phase: discovery Candidate: TetraKit Description: Target: CD44v6 Partner/co-funding: Co-funded by Eureka under the Eurostars project. Partners includes Pre-TT and Akiram Therapeutics

TetraKit Technologies ApS
Ole Maaløes Vej 3, DK-2200 Copenhagen Denmark

About:

About Company Partnerships Funding

Science:

Platform Pipeline

Other:

News Team Contact Careers

Legal:

Connect with us:

© 2022 TetraKit Technologies. All rights reserved